Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ipilimumab/nivolumab/pembrolizumab

Immune related adverse events : 4 case reports

    This is a preview of subscription content, log in to check access.

    Reference

    1. Wang LX, et al. Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. Cancer 126: 322-328, No. 2, 15 Jan 2020. Available from: URL: http://doi.org/10.1002/cncr.32542

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Ipilimumab/nivolumab/pembrolizumab. Reactions Weekly 1791, 151 (2020). https://doi.org/10.1007/s40278-020-74996-z

    Download citation